iGlarLixi, a once‐daily, fixed‐ratio combination of insulin glargine 100 U/mL (iGlar; a once‐daily basal insulin) and the GLP‐1 RA, lixisenatide (Lixi), has been shown to result in improved glycaemic control versus its individual components in both insulin‐naïve and insulin‐experienced people with T2D.6, 7, 8. This evidence concerns the gene INS and type 2 diabetes mellitus.